Neurobiology of Aging
Volume 29, Issue 8 , Pages 1140-1142 , August 2008

What does it take to stay healthy past 100? Commentary on “No disease in the brain of a 115-year-old woman”

Received 15 April 2008 ,Accepted 22 April 2008.

References 

  1. Arrigada PV, Marzloff K, Hyman B. Distribution of Alzheimer type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 1992;42:1681–1688
  2. Bales KR, Dodart JC, DeMattos RB, Holtzman DM, Paul SM. Apolipoprotein E, amyloid, and Alzheimer disease. Mol. Interv. 2002;2(6):363–375
  3. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging. 1997;18(July–August (4)):351–357
  4. Brendza RP, Holtzman DM. Amyloid-beta immunotherapies in mice and men. Alzheimer Dis. Assoc. Disord. 2006;20(2):118–123
  5. Duyckaerts C, Hauw JJ. Prevalence, incidence and duration of Braak's stages in the general population: can we know?. Neurobiol. Aging. 1997;18(July–August (4)):362–369
  6. Fitzpatrick AL, Kuller LH, Ives DG, Lopez OL, Jagust W, Breitner JC, et al. Incidence and prevalence of dementia in the Cardiovascular Health Study. J. Am. Geriatr. Soc. 2004 Feb;52(2):195–204
  7. Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol. Aging. 2002;23(November–December (6)):1009–1016
  8. Giannakopoulos P, Hof PR, Mottier S, Michel JP, Bouras C. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol. (Berl.). 1994;87(5):456–468
  9. Golde TE. Disease modifying therapy for AD?. J. Neurochem. 2006;99(3):689–707
  10. Goldman WP, Price JL, Storandt M, Grant EA, McKeel DW, Rubin EH, et al. Absence of cognitive impairment or decline in preclinical Alzheimer's disease. Neurology. 2001;56:361–367
  11. Gomez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci. 1996;16(July (14)):4491–4500
  12. Hyman BT, Van Hoesen GW, Kromer LJ, Damasio AR. Perforant pathway changes and the memory impairment of Alzheimer's disease. Ann. Neurol. 1986;20(4):472–481
  13. Hyman BT, Van Hoesen GW, Damasio AR. Memory-related neural systems in Alzheimer's disease: an anatomic study. Neurology. 1990;40(11):1721–1730
  14. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, Schellenberg GD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch. Neurol. 2002;59(11):1737–1746
  15. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology. 1999;52(1):78–84
  16. McKeel DW, Price JL, Miller JP, Grant EA, Xiong C, Berg L, et al. Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. J. Neuropathol. Exp. Neurol. 2004;63(10):1028–1037
  17. Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, et al. APOE genotype predicts when – not whether – one is predisposed to develop Alzheimer disease. Nat. Genet. 1998;19(4):321–322
  18. Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446–452
  19. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479–486
  20. Morris JC, Price JL. Pathological correlates of nondemented aging mild cognitive impairment and early stage Alzheimer's disease. J. Mol. Neursoci. 2001;17:101–118
  21. Morris JC, Storandt M, McKeel DW, Rubin EH, Price JL, Grant EA, et al. Cerebral amyloid deposition and diffuse plaques in “normal” aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996;46:707–719
  22. Price JL. Tangles and plaques in healthy aging and Alzheimer's disease. Independence or interaction?. Semin. Neurosci. 1994;6:395–402
  23. Price JL, Morris JC. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease. Ann. Neurol. 1999;45:13290–13295
  24. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch. Neurol. 2001;58:1395–1402
  25. Selkoe DJ. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N.Y. Acad. Sci. 2000;924:17–25
  26. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001;81:741–766
  27. Silverman W, Wisniewski HM, Bobinski M, Wegiel J. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging. 1997;18(4):377–379
  28. Troncoso JC, Martin LJ, Dal Forno G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol. Aging. 1996;17:365–371

PII: S0197-4580(08)00138-3

doi: 10.1016/j.neurobiolaging.2008.04.011

Neurobiology of Aging
Volume 29, Issue 8 , Pages 1140-1142 , August 2008

Article Tools